<DOC>
	<DOCNO>NCT00748501</DOCNO>
	<brief_summary>The purpose study evaluate effect investigational drug , SB-509 progression disease subject ALS</brief_summary>
	<brief_title>Clinical Trial SB-509 Subjects With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>SB-509 contains gene ( DNAâ€”a kind biological `` blueprint '' ) protein . When study doctor inject SB-509 muscle neck , arm and/or leg , drug enters muscle nerve cell around injection site cause cell make protein . This protein cause cell increase production one protein call vascular endothelial growth factor ( VEGF-A ) , may improve structure function nerve muscle . In addition , change level 28 additional protein cell . These protein function promote growth cell , structure cell , help synthesize product , affect immune cell , unknown function . This increase VEGF proteins may protect repair damaged nerve muscle cause ALS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Male female age 18 85 clinical diagnosis ALS Forced Vital Capacity ( FVC ) &gt; 60 % predict Less 3 year ALS since onset first symptom clinical evidence limb muscle atrophy weakness . Subjects take Riluzole must stable dose least 30 day evidence toxicity Female childbearing potential male childcreating potential must agree use medically acceptable physical barrier ( condom , diaphragm , cervical cap ) treatment phase least 30 day last study treatment . Women pregnant currently breastfeed Dependent upon invasive noninvasive artificial ventilation Patients bulbar onset ALS active neuromuscular/ neurodegenerative disease . Type 1 Type 2 diabetes . Evidence chronic active heart , liver , kidney , lung disease , Agerelated macular degeneration . Current history know immune immunodeficiency disorder Patients cognitive impairment significant decision make incapacity , major depression , schizophrenia , dementia ( e.g . Alzheimer 's disease ) . Malignancy history malignancy , except complete remission least 5 year Precancerous condition ( e.g . Barrett 's Esophagus , dysplasia ) benign tumor potential significant growth due VEGF stimulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis ,</keyword>
	<keyword>ALS ,</keyword>
	<keyword>Lou Gehrig 's Disease</keyword>
</DOC>